Dr. Marc Better brings unparalleled expertise in cell therapy and biologics process development and manufacturing to Cell One Partners. With over 30 years of experience in cell therapy and biologics CMC (Chemistry, Manufacturing, and Controls), Dr. Better has a comprehensive background in upstream, downstream, analytical, and drug product process development. His extensive knowledge spans non-GMP and GMP manufacturing, Quality by Design, commercial manufacturing support, technology transfer, and contract manufacturing of cell therapy products and recombinant proteins. As a Core Team member, he provides invaluable insights into regulatory interactions, ensuring compliance and facilitating the approval of innovative therapies.

​

Previously, Dr. Better served as Senior Vice President of Product Science at Kite Pharma, where he led a team of 85 scientists and engineers. He was responsible for process development, technology transfer, manufacturing support, and overall CMC activities for both autologous and allogeneic engineered T cell therapeutics. Under his leadership, Kite successfully completed CMC activities leading to the US licensure of Yescarta, the first-in-class anti-CD19 CAR T cell therapy, in October 2017. Dr. Better's extensive regulatory interactions worldwide, including in the US, EU, Canada, China, and Japan, further highlight his significant contributions to the field.